AL-37807 + latanoprost

AL-37807 + latanoprost is an investigational fixed-dose combination ophthalmic solution comprising AL-37807 and latanoprost, developed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. - **AL-37807** is a serotonergic ligand developed by Alcon; it was investigated as a novel agent for IOP lowering and reached phase II clinical development but has not been approved. - **Latanoprost** is a prostaglandin F2 alpha analog approved for IOP reduction, acting by increasing uveoscleral outflow. The combination aims to leverage the potentially additive or synergistic hypotensive effects of both agents, with complementary mechanisms. Clinical data are limited, and the combination has not been approved or marketed.